

Antonino Belfiore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5354098/publications.pdf>

Version: 2024-02-01

196
papers

12,819
citations

17440

63
h-index

26613

107
g-index

203
all docs

203
docs citations

203
times ranked

12135
citing authors

#	ARTICLE	IF	CITATIONS
1	Obesity, Diabetes, and Cancer: The Role of the Insulin/IGF Axis; Mechanisms and Clinical Implications. <i>Biomolecules</i> , 2022, 12, 612.	4.0	3
2	IFN-I signaling in cancer: the connection with dysregulated Insulin/IGF axis. <i>Trends in Endocrinology and Metabolism</i> , 2022, 33, 569-586.	7.1	3
3	Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	9
4	Triple-negative breast cancer drug resistance, durable efficacy, and cure: how advanced biological insights and emerging drug modalities could transform progress. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 513-535.	3.4	6
5	Insulin autoimmune syndrome misdiagnosed as an insulinoma in a woman presenting with a pancreatic cystic lesion and taking alpha lipoic acid: a lesson to be learned. <i>Hormones</i> , 2021, 20, 593-595.	1.9	4
6	Onset of Marine-Lenhart syndrome and Gravesâ€™ ophthalmopathy in a female patient treated with alemtuzumab for multiple sclerosis. <i>Hormones</i> , 2021, 20, 161-165.	1.9	2
7	Activation of the S100A7/RAGE Pathway by IGF-1 Contributes to Angiogenesis in Breast Cancer. <i>Cancers</i> , 2021, 13, 621.	3.7	22
8	DDR1 Affects Metabolic Reprogramming in Breast Cancer Cells by Cross-Talking to the Insulin/IGF System. <i>Biomolecules</i> , 2021, 11, 926.	4.0	9
9	Preventive Anti-inflammatory Diet to Reduce Gastrointestinal Inflammation in Familial Adenomatous Polyposis Patients: A Prospective Pilot Study. <i>Cancer Prevention Research</i> , 2021, 14, 963-972.	1.5	8
10	Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2021, 2021, .	0.5	8
11	Insulin Receptor Isoforms Differently Regulate Cell Proliferation and Apoptosis in the Ligand-Occupied and Unoccupied State. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8729.	4.1	6
12	Estrogen receptor variant ER α 46 and insulin receptor drive in primary breast cancer cells growth effects and interleukin 11 induction prompting the motility of cancer-associated fibroblasts. <i>Clinical and Translational Medicine</i> , 2021, 11, e516.	4.0	3
13	Novel Mechanisms of Tumor Promotion by the Insulin Receptor Isoform A in Triple-Negative Breast Cancer Cells. <i>Cells</i> , 2021, 10, 3145.	4.1	14
14	Concentration of Metals and Trace Elements in the Normal Human and Rat Thyroid: Comparison with Muscle and Adipose Tissue and Volcanic Versus Control Areas. <i>Thyroid</i> , 2020, 30, 290-299.	4.5	11
15	COVID-19 and Diabetes: The Importance of Controlling RAGE. <i>Frontiers in Endocrinology</i> , 2020, 11, 526.	3.5	33
16	The IL1 β -IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs). <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 153.	8.6	43
17	Microenvironmental Determinants of Breast Cancer Metastasis: Focus on the Crucial Interplay Between Estrogen and Insulin/Insulin-Like Growth Factor Signaling. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 608412.	3.7	16
18	Evidence That Baseline Levels of Low-Density Lipoproteins Cholesterol Affect the Clinical Response of Gravesâ€™ Ophthalmopathy to Parenteral Corticosteroids. <i>Frontiers in Endocrinology</i> , 2020, 11, 609895.	3.5	19

#	ARTICLE	IF	CITATIONS
19	Progranulin/EphA2 axis: A novel oncogenic mechanism in bladder cancer. <i>Matrix Biology</i> , 2020, 93, 10-24.	3.6	25
20	Increased Thyroid Cancer Incidence in Volcanic Areas: A Role of Increased Heavy Metals in the Environment?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3425.	4.1	20
21	Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism. <i>Frontiers in Endocrinology</i> , 2020, 11, 367.	3.5	4
22	The G Protein-Coupled Estrogen Receptor (GPER) Expression Correlates with Pro-Metastatic Pathways in ER-Negative Breast Cancer: A Bioinformatics Analysis. <i>Cells</i> , 2020, 9, 622.	4.1	28
23	Cancer associated fibroblasts: role in breast cancer and potential as therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 559-572.	3.4	42
24	Discoidin Domain Receptor 1 functionally interacts with the IGF-I system in bladder cancer. <i>Matrix Biology Plus</i> , 2020, 6-7, 100022.	3.5	7
25	DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop. <i>Endocrine-Related Cancer</i> , 2019, 26, 197-214.	3.1	38
26	Insulin/IGF signaling and discoidin domain receptors: An emerging functional connection. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019, 1866, 118522.	4.1	25
27	Thyroidectomy as Treatment of Choice for Differentiated Thyroid Cancer. <i>International Journal of Surgical Oncology</i> , 2019, 2019, 1-7.	0.6	5
28	Insulin Receptor Isoform A Modulates Metabolic Reprogramming of Breast Cancer Cells in Response to IGF2 and Insulin Stimulation. <i>Cells</i> , 2019, 8, 1017.	4.1	23
29	Response to Letter to the Editor: "Time to Separate Persistent From Recurrent Differentiated Thyroid Cancer: Different Conditions With Different Outcomes". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5110-5111.	3.6	2
30	A Pilot Low-Inflammatory Dietary Intervention to Reduce Inflammation and Improve Quality of Life in Patients With Familial Adenomatous Polyposis: Protocol Description and Preliminary Results. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541984640.	2.0	10
31	GPER Mediates a Feedforward FGF2/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells Toward Breast Tumor Progression. <i>Cells</i> , 2019, 8, 223.	4.1	41
32	Short-term adverse effects of anticancer drugs in patients with type 2 diabetes. <i>Journal of Chemotherapy</i> , 2019, 31, 150-159.	1.5	9
33	Time to Separate Persistent From Recurrent Differentiated Thyroid Cancer: Different Conditions With Different Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 258-265.	3.6	48
34	Effect of low-dose tungsten on human thyroid stem/precursor cells and their progeny. <i>Endocrine-Related Cancer</i> , 2019, 26, 713-725.	3.1	10
35	A novel functional crosstalk between DDR1 and the IGF axis and its relevance for breast cancer. <i>Cell Adhesion and Migration</i> , 2018, 12, 1-10.	2.7	24
36	Long-acting insulin analogs and cancer. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 436-443.	2.6	26

#	ARTICLE	IF	CITATIONS
37	Lymph node location is a risk factor for papillary thyroid cancer-related death. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 1349-1353.	3.3	19
38	Efficacy of Botulinum Toxin A for Treating Cramps in Diabetic Neuropathy. <i>Annals of Neurology</i> , 2018, 84, 674-682.	5.3	12
39	Differentiated thyroid cancer in children: Heterogeneity of predictive risk factors. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27226.	1.5	10
40	Analysis of Progranulin-Mediated Akt and MAPK Activation. <i>Methods in Molecular Biology</i> , 2018, 1806, 121-130.	0.9	7
41	Editorial: Clinical and Molecular Epidemiology of Thyroid Cancer of Follicular Origin. <i>Frontiers in Endocrinology</i> , 2018, 9, 67.	3.5	7
42	GP67, IGF1R, and EGFR transduction signaling are involved in stimulatory effects of zinc in breast cancer cells and cancer-associated fibroblasts. <i>Molecular Carcinogenesis</i> , 2017, 56, 580-593.	2.7	43
43	Seasonal variations in TSH serum levels in athyreotic patients under L-thyroxine replacement monotherapy. <i>Clinical Endocrinology</i> , 2017, 87, 207-215.	2.4	16
44	The perlecan-interacting growth factor progranulin regulates ubiquitination, sorting, and lysosomal degradation of sortilin. <i>Matrix Biology</i> , 2017, 64, 27-39.	3.6	26
45	Insulin Receptor Isoforms in Physiology and Disease: An Updated View. <i>Endocrine Reviews</i> , 2017, 38, 379-431.	20.1	270
46	The lauric acid-activated signaling prompts apoptosis in cancer cells. <i>Cell Death Discovery</i> , 2017, 3, 17063.	4.7	79
47	Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production. <i>Scientific Reports</i> , 2017, 7, 15992.	3.3	102
48	Recent views of heavy metals as possible risk factors and potential preventive and therapeutic agents in prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2017, 457, 57-72.	3.2	42
49	Recent advances on the stimulatory effects of metals in breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2017, 457, 49-56.	3.2	39
50	Growth hormone deficiency and hypopituitarism in adults after complicated mild traumatic brain injury. <i>Endocrine</i> , 2017, 58, 115-123.	2.3	33
51	PPAR- γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis. <i>Frontiers in Endocrinology</i> , 2017, 8, 31.	3.5	72
52	Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?. <i>Frontiers in Endocrinology</i> , 2017, 8, 314.	3.5	42
53	Recent Advances on the Role of microRNAs in both Insulin Resistance and Cancer. <i>Current Pharmaceutical Design</i> , 2017, 23, 3658-3666.	1.9	17
54	Discoïdin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells. <i>Oncotarget</i> , 2017, 8, 43248-43270.	1.8	35

#	ARTICLE	IF	CITATIONS
55	Abstract 1344: Progranulin promotes ubiquitination, sorting and lysosomal degradation of sortilin in castration-resistant prostate cancer cells. , 2017, , .		0
56	Stimulatory actions of IGF-I are mediated by IGF-IR cross-talk with GPER and DDR1 in mesothelioma and lung cancer cells. <i>Oncotarget</i> , 2016, 7, 52710-52728.	1.8	35
57	Mechanisms of Progranulin Action and Regulation in Genitourinary Cancers. <i>Frontiers in Endocrinology</i> , 2016, 7, 100.	3.5	19
58	Evaluation of the CD44 isoform v-6 (sCD44var, v6) in the saliva of patients with laryngeal carcinoma and its prognostic role. <i>Cancer Biomarkers</i> , 2016, 16, 275-280.	1.7	5
59	GPER signalling in both cancer-associated fibroblasts and breast cancer cells mediates a feedforward IL1 β /IL1R1 response. <i>Scientific Reports</i> , 2016, 6, 24354.	3.3	64
60	MP61-13 PROGRANULIN TARGETING IN UROTHELIAL CANCER CELLS INHIBITS MOTILITY, ANCHORAGE-INDEPENDENT GROWTH, TUMOR FORMATION IN VIVO AND SENSITIZES CELLS TO CISPLATIN. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
61	Recent Advances on the Role of G Protein-Coupled Receptors in Hypoxia-Mediated Signaling. <i>AAPS Journal</i> , 2016, 18, 305-310.	4.4	23
62	The G protein estrogen receptor (GPER) is regulated by endothelin-1 mediated signaling in cancer cells. <i>Cellular Signalling</i> , 2016, 28, 61-71.	3.6	23
63	GPER is involved in the stimulatory effects of aldosterone in breast cancer cells and breast tumor-derived endothelial cells. <i>Oncotarget</i> , 2016, 7, 94-111.	1.8	57
64	IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway. <i>Oncotarget</i> , 2016, 7, 7683-7700.	1.8	69
65	Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin. <i>Oncotarget</i> , 2016, 7, 39980-39995.	1.8	26
66	Abstract 4612: In breast cancer cells IGF-I induces upregulation of DDR1 by suppressing miR-199a-5p via the PI3K/Akt pathway. , 2016, , .		0
67	Abstract 698: Progranulin targeting in urothelial cancer cells inhibits motility, tumor growth in vitro and in vivo and sensitizes cells to cisplatin. , 2016, , .		0
68	Novel Aspects Concerning the Functional Cross-Talk between the Insulin/IGF-I System and Estrogen Signaling in Cancer Cells. <i>Frontiers in Endocrinology</i> , 2015, 6, 30.	3.5	42
69	Copper activates HIF-1 β /GPER/VEGF signalling in cancer cells. <i>Oncotarget</i> , 2015, 6, 34158-34177.	1.8	128
70	Thyrospheres From Normal or Malignant Thyroid Tissue Have Different Biological, Functional, and Genetic Features. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1168-E1178.	3.6	29
71	A calixpyrrole derivative acts as a GPER antagonist: mechanisms and models. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1237-46.	2.4	32
72	Sortilin Regulates Progranulin Action in Castration-Resistant Prostate Cancer Cells. <i>Endocrinology</i> , 2015, 156, 58-70.	2.8	38

#	ARTICLE	IF	CITATIONS
73	Novel cross-talk between IGF-IR and DDR1 regulates IGF-IR trafficking, signaling and biological responses. <i>Oncotarget</i> , 2015, 6, 16084-16105.	1.8	57
74	A novel role for drebrin in regulating progranulin bioactivity in bladder cancer. <i>Oncotarget</i> , 2015, 6, 10825-10839.	1.8	44
75	Abstract 4945: A novel role for drebrin in regulating progranulin bioactivity in bladder cancer. , 2015, , .		0
76	The Emerging Role of Insulin and Insulin-Like Growth Factor Signaling in Cancer Stem Cells. <i>Frontiers in Endocrinology</i> , 2014, 5, 10.	3.5	122
77	New insights on the Intrinsic, Pro-Apoptotic Effect of IGFB3 in Breast Cancer. <i>Frontiers in Endocrinology</i> , 2014, 5, 176.	3.5	2
78	Ligand-Mediated Endocytosis and Trafficking of the Insulin-Like Growth Factor Receptor I and Insulin Receptor Modulate Receptor Function. <i>Frontiers in Endocrinology</i> , 2014, 5, 220.	3.5	35
79	GPER Mediates Activation of HIF1 \pm /VEGF Signaling by Estrogens. <i>Cancer Research</i> , 2014, 74, 4053-4064.	0.9	105
80	Metformin Inhibits Androgen-Induced IGF-IR Up-Regulation in Prostate Cancer Cells by Disrupting Membrane-Initiated Androgen Signaling. <i>Endocrinology</i> , 2014, 155, 1207-1221.	2.8	50
81	Decorin differentially modulates the activity of insulin receptor isoform A ligands. <i>Matrix Biology</i> , 2014, 35, 82-90.	3.6	47
82	In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 132-139.	2.6	40
83	Prognostic role of salivary <sc>CD</sc>44sol levels in the followâ€up of laryngeal carcinomas. <i>Journal of Oral Pathology and Medicine</i> , 2014, 43, 276-281.	2.7	10
84	GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts. <i>Endocrine-Related Cancer</i> , 2014, 21, 739-753.	3.1	37
85	Niacin activates the G protein estrogen receptor (GPER)-mediated signalling. <i>Cellular Signalling</i> , 2014, 26, 1466-1475.	3.6	42
86	Abstract 4415: Discoidin domain receptor 1 (DDR1) and IGF-I system crosstalk in bladder cancer progression. , 2014, , .		0
87	Increased Mortality in Patients With Differentiated Thyroid Cancer Associated With Graves' Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1014-1021.	3.6	66
88	HIF-1 \pm /GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). <i>Breast Cancer Research</i> , 2013, 15, R64.	5.0	173
89	Cross-talk between GPER and growth factor signaling. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 137, 50-56.	2.5	73
90	Insulin-like growth factor-I regulates GPER expression and function in cancer cells. <i>Oncogene</i> , 2013, 32, 678-688.	5.9	86

#	ARTICLE	IF	CITATIONS
91	Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment. International Journal of Molecular Sciences, 2013, 14, 22933-22966.	4.1	88
92	Grand Challenges in Cancer Endocrinology: Endocrine Related Cancers, an Expanding Concept. Frontiers in Endocrinology, 2013, 4, 141.	3.5	6
93	Metformin as an Adjuvant Drug against Pediatric Sarcomas: Hypoxia Limits Therapeutic Effects of the Drug. PLoS ONE, 2013, 8, e83832.	2.5	43
94	GPER Mediates Cardiotropic Effects in Spontaneously Hypertensive Rat Hearts. PLoS ONE, 2013, 8, e69322.	2.5	48
95	Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis. Current Pharmaceutical Design, 2013, 19, 5344-5361.	1.9	8
96	Bisphenol A Induces Gene Expression Changes and Proliferative Effects through GPER in Breast Cancer Cells and Cancer-Associated Fibroblasts. Environmental Health Perspectives, 2012, 120, 1177-1182.	6.0	234
97	Insulin and Insulin-like Growth Factor II Differentially Regulate Endocytic Sorting and Stability of Insulin Receptor Isoform A. Journal of Biological Chemistry, 2012, 287, 11422-11436.	3.4	76
98	Identification of Common and Distinctive Mechanisms of Resistance to Different Anti-IGF-IR Agents in Ewing's Sarcoma. Molecular Endocrinology, 2012, 26, 1603-1616.	3.7	53
99	Elisa Detection of Salivary Levels of Cd44sol as a Diagnostic Test for Laryngeal Carcinomas. Journal of Cancer Science & Therapy, 2012, 04, .	1.7	10
100	The Role of Metformin in the Management of NAFLD. Experimental Diabetes Research, 2012, 2012, 1-13.	3.8	150
101	Proinsulin Binds with High Affinity the Insulin Receptor Isoform A and Predominantly Activates the Mitogenic Pathway. Endocrinology, 2012, 153, 2152-2163.	2.8	87
102	Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma Cells. PLoS ONE, 2012, 7, e40148.	2.5	22
103	The Insulin and IGF-I Pathway in Endocrine Glands Carcinogenesis. Journal of Oncology, 2012, 2012, 1-19.	1.3	23
104	GPER mediates the Egr-1 expression induced by 17 β -estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells. Breast Cancer Research and Treatment, 2012, 133, 1025-1035.	2.5	84
105	New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer. Cellular Signalling, 2012, 24, 1515-1521.	3.6	63
106	Targeting the Insulin-Like Growth Factor (IGF) System Is Not as Simple as Just Targeting the Type 1 IGF Receptor. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 599-604.	3.8	7
107	Overlaps Between the Insulin and IGF-I Receptor and Cancer. , 2012, , 263-278.		0
108	The IGF-I Axis in Prostate Cancer: The Role of Rapid Steroid Actions. , 2012, , 193-212.		0

#	ARTICLE	IF	CITATIONS
109	The Insulin Receptor: A New Target for Cancer Therapy. <i>Frontiers in Endocrinology</i> , 2011, 2, 93.	3.5	72
110	Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. <i>Oncogene</i> , 2011, 30, 2730-2740.	5.9	119
111	Research Resource: New and Diverse Substrates for the Insulin Receptor Isoform A Revealed by Quantitative Proteomics After Stimulation With IGF-II or Insulin. <i>Molecular Endocrinology</i> , 2011, 25, 1456-1468.	3.7	48
112	Insulin Receptor Isoforms and Insulin-Like Growth Factor Receptor in Human Follicular Cell Precursors from Papillary Thyroid Cancer and Normal Thyroid. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 766-774.	3.6	130
113	Insulin receptor and cancer. <i>Endocrine-Related Cancer</i> , 2011, 18, R125-R147.	3.1	233
114	The G Protein-coupled Receptor 30 Is Up-regulated by Hypoxia-inducible Factor-1 α (HIF-1 α) in Breast Cancer Cells and Cardiomyocytes. <i>Journal of Biological Chemistry</i> , 2011, 286, 10773-10782.	3.4	93
115	IGF-I and Insulin Receptor Families in Cancer. <i>Energy Balance and Cancer</i> , 2011, , 243-268.	0.2	1
116	Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. <i>International Journal of Obesity</i> , 2010, 34, 1255-1264.	3.4	111
117	Identification of Insulin-Like Growth Factor-I Receptor (IGF-IR) Gene Promoter-Binding Proteins in Estrogen Receptor (ER)-Positive and ER-Depleted Breast Cancer Cells. <i>Cancers</i> , 2010, 2, 233-261.	3.7	30
118	Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. <i>Molecular and Cellular Endocrinology</i> , 2010, 320, 162-170.	3.2	106
119	HMGA1 protein is a positive regulator of the insulin-like growth factor-I receptor gene. <i>European Journal of Cancer</i> , 2010, 46, 1919-1926.	2.8	32
120	PPAR- α Agonists and Their Effects on IGF-I Receptor Signaling: Implications for Cancer. <i>PPAR Research</i> , 2009, 2009, 1-18.	2.4	92
121	Role of Cyclic AMP Response Element-Binding Protein in Insulin-like Growth Factor-I Receptor Up-regulation by Sex Steroids in Prostate Cancer Cells. <i>Cancer Research</i> , 2009, 69, 7270-7277.	0.9	41
122	Differential Signaling Activation by Insulin and Insulin-Like Growth Factors I and II upon Binding to Insulin Receptor Isoform A. <i>Endocrinology</i> , 2009, 150, 3594-3602.	2.8	64
123	Sex Steroids Upregulate the IGF-1R in Prostate Cancer Cells through a Nongenotropic Pathway. <i>Annals of the New York Academy of Sciences</i> , 2009, 1155, 263-267.	3.8	14
124	Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease. <i>Endocrine Reviews</i> , 2009, 30, 586-623.	20.1	889
125	A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 603-614.	2.8	63
126	Clinical Evolution of Autoimmune Thyroiditis in Children and Adolescents. <i>Thyroid</i> , 2009, 19, 361-367.	4.5	25

#	ARTICLE	IF	CITATIONS
127	IGF and Insulin Receptor Signaling in Breast Cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2008, 13, 381-406.	2.7	122
128	Relationship between high prolactin levels and migraine attacks in patients with microprolactinoma. <i>Journal of Headache and Pain</i> , 2008, 9, 103-107.	6.0	37
129	BRAF(V600E) mutation and the biology of papillary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2008, 15, 191-205.	3.1	210
130	The role of insulin receptors and IGF-I receptors in cancer and other diseases. <i>Archives of Physiology and Biochemistry</i> , 2008, 114, 23-37.	2.1	365
131	Role of c-Abl in Directing Metabolic versus Mitogenic Effects in Insulin Receptor Signaling. <i>Journal of Biological Chemistry</i> , 2007, 282, 26077-26088.	3.4	29
132	The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer. <i>Current Pharmaceutical Design</i> , 2007, 13, 671-686.	1.9	230
133	17 β -Estradiol Up-regulates the Insulin-like Growth Factor Receptor through a Nongenotropic Pathway in Prostate Cancer Cells. <i>Cancer Research</i> , 2007, 67, 8932-8941.	0.9	35
134	Functional responses and in vivo anti-tumour activity of h7C10: A humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. <i>European Journal of Cancer</i> , 2007, 43, 1318-1327.	2.8	65
135	Peroxisomal Proliferator-Activated Receptor- γ Agonists Induce Partial Reversion of Epithelial-Mesenchymal Transition in Anaplastic Thyroid Cancer Cells. <i>Endocrinology</i> , 2006, 147, 4463-4475.	2.8	96
136	Androgens Up-regulate the Insulin-like Growth Factor-I Receptor in Prostate Cancer Cells. <i>Cancer Research</i> , 2005, 65, 1849-1857.	0.9	188
137	Interleukin-4 Stimulates Papillary Thyroid Cancer Cell Survival: Implications in Patients with Thyroid Cancer and Concomitant Graves' Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2880-2889.	3.6	35
138	Activation of the Hepatocyte Growth Factor (HGF)-Met System in Papillary Thyroid Cancer: Biological Effects of HGF in Thyroid Cancer Cells Depend on Met Expression Levels. <i>Endocrinology</i> , 2004, 145, 4355-4365.	2.8	45
139	Clinical Behavior and Outcome of Papillary Thyroid Cancers Smaller than 1.5 cm in Diameter: Study of 299 Cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 3713-3720.	3.6	299
140	Neural Network Analysis for Evaluating Cancer Risk in Thyroid Nodules with an Indeterminate Diagnosis at Aspiration Cytology: Identification of a Low-Risk Subgroup. <i>Thyroid</i> , 2004, 14, 1065-1071.	4.5	33
141	IGF-II Binding to Insulin Receptor Isoform A Induces a Partially Different Gene Expression Profile from Insulin Binding. <i>Annals of the New York Academy of Sciences</i> , 2004, 1028, 450-456.	3.8	42
142	Differential expression of mucins 1-6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ. <i>Journal of Pathology</i> , 2003, 200, 357-369.	4.5	14
143	Signaling Differences from the A and B Isoforms of the Insulin Receptor (IR) in 32D Cells in the Presence or Absence of IR Substrate-1. <i>Endocrinology</i> , 2003, 144, 2650-2658.	2.8	88
144	Differential Gene Expression Induced by Insulin and Insulin-like Growth Factor-II through the Insulin Receptor Isoform A. <i>Journal of Biological Chemistry</i> , 2003, 278, 42178-42189.	3.4	86

#	ARTICLE	IF	CITATIONS
145	Insulin/Insulin-like Growth Factor I Hybrid Receptors Have Different Biological Characteristics Depending on the Insulin Receptor Isoform Involved. <i>Journal of Biological Chemistry</i> , 2002, 277, 39684-39695.	3.4	413
146	A Novel Autocrine Loop Involving IGF-II and the Insulin Receptor Isoform-A Stimulates Growth of Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 245-254.	3.6	216
147	Long-term outcome of patients with insular carcinoma of the thyroid. <i>Cancer</i> , 2002, 95, 2076-2085.	4.1	77
148	In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. <i>Oncogene</i> , 2002, 21, 8240-8250.	5.9	150
149	A Novel Autocrine Loop Involving IGF-II and the Insulin Receptor Isoform-A Stimulates Growth of Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 245-254.	3.6	58
150	FINE-NEEDLE ASPIRATION BIOPSY OF THE THYROID. <i>Endocrinology and Metabolism Clinics of North America</i> , 2001, 30, 361-400.	3.2	126
151	Graves' disease, thyroid nodules and thyroid cancer. <i>Clinical Endocrinology</i> , 2001, 55, 711-718.	2.4	119
152	Immunostaining for Met/HGF Receptor May be Useful to Identify Malignancies in Thyroid Lesions Classified Suspicious at Fine-Needle Aspiration Biopsy. <i>Thyroid</i> , 2001, 11, 783-787.	4.5	23
153	The IGF system in thyroid cancer: new concepts. <i>Journal of Clinical Pathology</i> , 2001, 54, 121-124.	1.9	155
154	Appearance of Antithyroglobulin Antibodies as the Sole Sign of Metastatic Lymph Nodes in a Patient Operated on for Papillary Thyroid Cancer: A Case Report. <i>Thyroid</i> , 2000, 10, 431-433.	4.5	17
155	Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. <i>Oncogene</i> , 1999, 18, 2471-2479.	5.9	261
156	Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. <i>Biochimie</i> , 1999, 81, 403-407.	2.6	96
157	Overexpression of the RON gene in human breast carcinoma. <i>Oncogene</i> , 1998, 16, 2927-2933.	5.9	190
158	Outcome of Differentiated Thyroid Cancer in Graves'™ Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2805-2809.	3.6	115
159	Outcome of Differentiated Thyroid Cancer in Graves' Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 2805-2809.	3.6	98
160	Detection of an Activating Mutation of the Thyrotropin Receptor in a Case of an Autonomously Hyperfunctioning Thyroid Insular Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 735-738.	3.6	91
161	<i>In Situ</i> Evidence of Neoplastic Cell Phagocytosis by Macrophages in Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 1615-1620.	3.6	46
162	Negative/Low Expression of the Met/Hepatocyte Growth Factor Receptor Identifies Papillary Thyroid Carcinomas with High Risk of Distant Metastases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 2322-2328.	3.6	64

#	ARTICLE	IF	CITATIONS
163	Transition from Cold to Hot Thyroid Nodules. <i>Thyroid</i> , 1997, 7, 897-900.	4.5	1
164	Insulin Receptor. <i>Trends in Endocrinology and Metabolism</i> , 1997, 8, 306-312.	7.1	24
165	Detection of an Activating Mutation of the Thyrotropin Receptor in a Case of an Autonomously Hyperfunctioning Thyroid Insular Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 735-738.	3.6	85
166	Negative/Low Expression of the Met/Hepatocyte Growth Factor Receptor Identifies Papillary Thyroid Carcinomas with High Risk of Distant Metastases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 2322-2328.	3.6	63
167	Insulin Receptors in Breast Cancer. <i>Annals of the New York Academy of Sciences</i> , 1996, 784, 173-188.	3.8	66
168	Interleukin-1 blocks insulin and insulin-like growth factor-stimulated growth in MCF-7 human breast cancer cells by inhibiting receptor tyrosine kinase activity. <i>Endocrinology</i> , 1996, 137, 4100-4107.	2.8	8
169	Cold thyroid nodule reduction with L-thyroxine can be predicted by initial nodule volume and cytological characteristics. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 4385-4387.	3.6	19
170	Overexpression of membrane glycoprotein PC-1 in MDA-MB231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity. <i>Molecular Endocrinology</i> , 1996, 10, 1318-1326.	3.7	31
171	Overexpression of the C-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. <i>Journal of Endocrinological Investigation</i> , 1995, 18, 134-139.	3.3	63
172	Early occurrence of a thyroid carcinoma in a patient who developed Graves's disease after treatment for Hodgkin's disease. <i>Journal of Endocrinological Investigation</i> , 1995, 18, 869-871.	3.3	4
173	Growth Inhibition of Human Endothelial Cells by Human Recombinant Tumor Necrosis Factor Alpha and Interferon-Gamma. <i>Tumori</i> , 1994, 80, 301-305.	1.1	5
174	False positive 131I total body scan due to an ectasia of the common carotidis. <i>Journal of Endocrinological Investigation</i> , 1993, 16, 207-211.	3.3	20
175	Insulin-resistant MDA-MB231 human breast cancer cells contain a tyrosine kinase inhibiting activity. <i>Molecular Endocrinology</i> , 1993, 7, 1667-1676.	3.7	13
176	HLA Class II Gene Expression in Human Thyroid Cells. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1992, 100, 17-21.	1.2	0
177	Induction of intercellular adhesion molecule-1 but not of lymphocyte function-associated antigen-3 in thyroid follicular cells. <i>Journal of Autoimmunity</i> , 1992, 5, 119-135.	6.5	26
178	Relation between steroid receptor status and body weight in breast cancer patients. <i>European Journal of Cancer</i> , 1992, 28, 112-115.	2.8	54
179	Cancer risk in patients with cold thyroid nodules: Relevance of iodine intake, sex, age, and multinodularity. <i>American Journal of Medicine</i> , 1992, 93, 363-369.	1.5	444
180	Effect of TSH in human thyroid cells: Evidence for both mitogenic and antimitogenic effects. <i>Journal of Cellular Biochemistry</i> , 1992, 49, 231-238.	2.6	31

#	ARTICLE	IF	CITATIONS
181	De novo HLA Class II and enhanced HLA Class I molecule expression in SV40 transfected human thyroid epithelial cells. <i>Journal of Autoimmunity</i> , 1991, 4, 397-414.	6.5	31
182	Ultrasound scanning assessment of L-Thyroxine treatment effectiveness in a group of children with diffuse goiter. <i>Journal of Endocrinological Investigation</i> , 1991, 14, 675-678.	3.3	7
183	Evaluation of the fine needle aspiration biopsy in the preoperative selection of cold thyroid nodules. <i>Cancer</i> , 1991, 67, 2137-2141.	4.1	122
184	Overexpression of Insulin Receptors in Fibroblast and Ovary Cells Induces a Ligand-Mediated Transformed Phenotype. <i>Molecular Endocrinology</i> , 1991, 5, 452-459.	3.7	91
185	The morphometric analysis of cell nuclei from fine needle aspirates of thyroid follicular lesions does not improve the diagnostic accuracy of traditional cytologic examination. <i>Journal of Endocrinological Investigation</i> , 1990, 13, 701-707.	3.3	14
186	Increased Aggressiveness of Thyroid Cancer in Patients with Graves' Disease*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 70, 830-835.	3.6	252
187	High frequency of cancer in cold thyroid nodules occurring at young age. <i>European Journal of Endocrinology</i> , 1989, 121, 197-202.	3.7	100
188	The Role of Thyroid-Stimulating Antibodies of Graves' Disease in Differentiated Thyroid Cancer. <i>New England Journal of Medicine</i> , 1988, 318, 753-759.	27.0	155
189	Thyocyte HLA class II expression and regulation in relation to thyroid autoimmunity. <i>European Journal of Endocrinology</i> , 1987, 116, S27-S34.	3.7	15
190	The frequency of cold thyroid nodules and thyroid malignancies in patients from an iodine-deficient area. <i>Cancer</i> , 1987, 60, 3096-3102.	4.1	146
191	Epithelial Expression of HLA Class II Molecules: A New Pathogenic Factor in Organ-Specific Autoimmunity. <i>Acta Medica Scandinavica</i> , 1987, 221, 79-83.	0.0	5
192	Organ-Specific Autoimmunity: A 1986 Overview. <i>Immunological Reviews</i> , 1986, 94, 137-169.	6.0	274
193	Solitary Autonomously Functioning Thyroid Nodules and Iodine Deficiency*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1983, 56, 283-287.	3.6	87
194	Role of thyrotrophin-releasing hormone in the development of pituitary-thyroid axis in four anencephalic infants. <i>European Journal of Endocrinology</i> , 1982, 101, 538-541.	3.7	4
195	High incidence of anti-GH antibodies in subjects treated with the GH clinical preparation available in Italy. <i>Journal of Endocrinological Investigation</i> , 1980, 3, 313-315.	3.3	3
196	Cholesterol and Graves' Orbitopathy (GO): A new decision-making algorithm based on baseline low density lipoprotein cholesterol (LDLc) and early GO clinical response to parenteral corticosteroids™. <i>Endocrine Abstracts</i> , 0, , .	0.0	0